Navigation Links
Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
Date:2/17/2010

GREENSBORO, N.C., Feb. 17 /PRNewswire/ -- Stretch marks can make even the most beautiful women feel insecure and self-conscious. Approximately 90% of pregnant women and 70% of adolescent females have stretch marks, and they also commonly occur in people who have lost weight within a brief time period. Although they pose no health risks, stretch marks can cause negative body image issues for women of all shapes and sizes. With new Mederma® Stretch Marks Therapy women now have an effective, clinically proven option to improve the appearance of their stretch marks.

From the makers of #1 doctor-recommended brand for scars for over a decade, Mederma® Stretch Marks Therapy is a patented formula that combines a unique blend of ingredients, including the proprietary botanical extract Cepalin®, hyaluronic acid and centella asiatica leaf extract. This advanced formula is dermatologist tested and clinically proven to reduce discoloration, improve texture and enhance skin's softness, with noticeable improvement in about 4 weeks, and optimum improvement in 12 weeks when used twice daily.

"Stretch marks are very common and occur when the skin is stretched beyond a certain degree, such as during pregnancy or in times of weight increase when the connective tissue can be disrupted and show unattractive red marks on the skin's surface," says Zoe Diana Draelos, MD, a clinical and research dermatologist based in High Point, North Carolina, with a special interest in problems associated with skin, hair and nails. "In the clinical trial, 80% of women noted visible improvement in their stretch marks compared to non treatment, with a trend toward improved elasticity."

"Stretch marks can be a nagging reminder to new moms who have worked hard to lose their baby weight," says Victoria Pericon of Mom Blog Savvymommy.com. "An effective product that could help to improve the appearance of their stretch marks would provide a real confidence boost for these women," she added.

Mederma® Stretch Marks Therapy is effective for all the areas of the body where stretch marks occur, including the arms, abdomen and buttocks. For best results, Mederma® Stretch Marks Therapy should be used as directed twice a day for 12 weeks.

Mederma® Stretch Marks Therapy is sold in a 5.29-oz tube and retails for $39.99. It is now available at CVS, Walgreens and in other drugstores nationwide.

About Mederma®

The Mederma® family of products, including Mederma® Gel, Mederma® Cream plus SPF 30, and Mederma® for Kids, has a long tradition of efficacy. The #1 doctor- and pharmacist-recommended brand for scars, Mederma® helps reduce the appearance of scars resulting from surgery, injury, burns, and acne, making them softer, smoother, and less noticeable. To learn more, visit www.mederma.com.

About Merz Pharmaceuticals

Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma®.

With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

SOURCE Merz Pharmaceuticals, LLC

RELATED LINKS
http://www.mederma.com

'/>"/>

SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... DUBLIN , Jan 18, 2017 Research ... Nausea and Vomiting Drugs Market 2017-2021" report to their offering. ... The global ... the period 2017-2021. Global Thoracic Surgery Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
(Date:1/18/2017)... SHANGHAI , Jan. 18, 2017 In ... of revolution, which is where the Upgrade of ... year of the 13th Five-Year Plan for Economic and Social ... (the 13th Five-Year Plan), and the state council of ... the "13th Five-Year" national strategic emerging industry development plan, identifying ...
(Date:1/18/2017)... Ximbio, a non-profit online one-stop-shop for the global ... first North American headquarters in Kendall Square, Cambridge, ... ... launch in October 2014 as a business unit of UK- ... the foundation Cancer Research UK. Ximbio.com allows scientists ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy Associates, Inc., ... Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, ... biosimilars through thought leader interaction in, live video and interactive digital platforms. , ...
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now ... in the corners and commit the crime of stalking, a very real danger to many ... often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. Stop ...
(Date:1/17/2017)... ... 17, 2017 , ... Today, to help those who are ... uplifting interview with medical expert and prolific author, Dr. Bernie Siegel. ... times, Dr. Bernie Siegel energizes listeners to live life with intrigue, magic and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a new 21st century approach to infusing high speed technology into the fabric ... exclusively dedicated to the advancement of healthcare and wellness in a yet-to-be-named, health ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
Breaking Medicine News(10 mins):